Genta Granted Extension to Achieve Compliance with NASDAQ Listing Re...(programs anchor the Company'sresearch pl...)

Date:3/27/2008

programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: http://www.genta.com.

Safe Harbor

This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Forward-looking statements include, without limitation, statements about:

-- the Company's ability to obtain necessary regulatory approval for

Genasense(R) from the U.S. Food and Drug Administration ("FDA") or

European Medicines Agency ("EMEA");

-- the safety and efficacy of the Company's products or product

candidates;

-- the Company's assessment of its clinical trials;

-- the commencement and completion of clinical trials;

<
'/>"/>

SOURCE Genta Incorporated Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. Auditors for Genta Incorporated Express Going Concern Qualification
2. Genta Announces Senior Management Changes
3. Genta Announces Common Stock Offering of Approximately $3.1 Million
4. Genta Incorporated to Present at the BIO CEO & Investor Conference
5. Genta Receives Notice of Non-Compliance With NASDAQ Rule
6. Genta Receives NASDAQ Non-Compliance Notice
7. Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference
8. Syngenta and The Royal Society of Chemistry Launch African Science Initiative
9. Genta Receives Notice of Non-Compliance with Listing Requirement for NASDAQ Global Market
10. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
11. Syngenta Licenses Chromatin Gene Stacking Technology